Personality assessment with Temperament and Character Inventory in Parkinson’s disease
Parkinsonism & Related Disorders. 2022-10-01; 103: 34-41
DOI: 10.1016/j.parkreldis.2022.08.004
Lire sur PubMed
Boussac M(1), Arbus C(2), Colin O(3), Laurencin C(4), Eusebio A(5), Hainque E(6), Corvol JC(6), Versace N(7), Rascol O(8), Rousseau V(9), Harroch E(9), Ory-Magne F(8), Fabbri M(8), Moreau C(10), Rolland AS(10), Jarraya B(11), Maltête D(12), Drapier S(13), Marques AR(14), Auzou N(15), Wirth T(16), Meyer M(17), Giordana B(18), Tir M(19), Rouaud T(20), Devos D(10), Brefel-Courbon C(8); PREDISTIM study group.
Collaborators: Moreau C(21), Defebvre PL(21), Carriere DN(21), Grolez DG(21),
Baille DG(21), Kreisler D(21), Jean-Pierre Pruvo P(21), Leclerc P(21), Lopes
DR(21), Viard DR(21), Kuchcinski DG(21), Dumont MJ(21), Dujardin PK(21),
Delliaux MM(21), Brion MM(21), Touzet DG(21), Reyns PN(21), Delval PA(21),
Santraine MV(21), Pleuvret MM(21), Dautrevaux MN(21), Laugeais MV(21), Ouk
T(21), Potey C(21), Leclercq C(21), Gers E(21), Corvol JC(22),
Marie-Vidailhet(22), Hainque E(22), Welter ML(22), Lacomblez L(22), Grabli
D(22), Roze E(22), Worbe Y(22), Delorme C(22), You H(22), Ihle J(22),
Guimeraes-Costa R(22), Cormier-Dequaire F(22), Méneret A(22), Hartmann A(22),
Mariani LL(22), Lehericy S(22), Czernecki V(22), Pineau F(22), Bozon F(22),
Huiban C(22), Benchetrit E(22), Karachi C(22), Navarro S(22), Cornu P(22),
Welaratne A(22), Dongmo-Kenfack C(22), Mantisi L(22), Jarry N(22), Aix S(22),
Lefort C(22), Rouaud DT(23), Damier PP(23), Derkinderen PP(23), Anne-Gaelle
Corbille D(23), Calvier-Auffray DE(23), Rocher ML(23), Anne-Laure Deruet M(23),
Sylvie DR(23), Vincent DR(23), Le Dily Séverine M(23), Marques DA(24), Debilly
DB(24), Durif PF(24), Derost DP(24), Beal DC(24), Chassain C(24), Delaby L(24),
Vidal T(24), Jacques Lemaire PJ(24), Rieu I(24), Durand E(24), Eusebio PA(25),
Jean-Philippe Azulay P(25), Witjas DT(25), Fluchère DF(25), Grimaldi DS(25),
Girard PN(25), Benchetrit E(25), Delfini M(25), Carron DR(25), Regis PJ(25),
Spatola DG(25), Magnaudet C(25), Solène DA(26), Isabelle DB(26), Olivier DC(26),
Houeto Jl P(26), Remy PG(26), Anne MF(26), Manssouri MA(26), Sophie MB(26),
Philippe DR(26), Philippe DC(26), Philippe DP(26), Benoit PB(26), Emilie MR(26),
Annie MG(26), Sophie DD(27), Leh DF(27), Bonnet DA(27), Vérin PM(27),
Jean-Christophe Ferré D(27), François Houvenaghel MJ(27), Haegelen PC(27),
Kestens MF(27), Ory MS(27), Burbaud PP(28), Damon-Perriere DN(28), Meissner
PW(28), Tison PF(28), Bannier DS(28), Krim DE(28), Guehl PD(28),
Molinier-Blossier S(28), Ollivier M(28), Lacoste M(28), Auzou N(28), Bonnet
M(28), Cuny PE(28), Engelhardt DJ(28), Branchard O(28), Huet C(28), Blanchard
J(28), Olivier PR(29), Brefel Courbon DC(29), Ory Magne DF(29), Simonetta Moreau
DM(29), Arbus PC(29), Bonneville PF(29), Albert Lotterie DJ(29), Sarrail M(29),
Scotto d’Apollonia C(29), Chaynes PP(29), Caire PF(29), Harroch E(29), Maltete
PD(30), Lefaucheur DR(30), Fetter DD(30), Magne DN(30), Bioux MS(30), Loubeyre
MM(30), Bliaux ME(30), Pouliquen MD(30), Derrey PS(30), Vernon ML(30), Ziegler
DF(30), Anheim M(31), Lagha-Boukbiza O(31), Tranchant C(31), Gebus O(31),
Montaut S(31), Kremer S(31), Longato N(31), Phillips C(31), Voirin J(31), Santin
MDN(31), Chaussemy D(31), Mengin DA(31), Giordana DC(32), Marsé DC(32), Mondot
L(32), Giordana B(32), Kardous R(32), Bailet B(32), Joly H(32), Fontaine D(32),
Leplus DA(32), Faustini A(32), Ferrier V(32), Krystkowiak PP(33), Tir DM(33),
Jean-Marc Constans P(33), Wannepain S(33), Seling A(33), Lefranc DM(33), Blin
S(33), Schuler B(33), Thobois PS(34), Danaila DT(34), Laurencin DC(34),
Berthezene PY(34), Ameli DR(34), Klinger H(34), Polo DG(34), Mertens P(34),
Nunes A(34), Metereau E(34), Hopes DL(35), Frismand DS(35), Schmitt DE(35),
Meyer MM(35), Dillier MC(35), Colnat PS(35), Chatelain MA(35), Philippe Brandel
DJ(36), Hubsch DC(36), Karsenti DP(36), Lebouteux DM(36), Ziegler DM(36),
Delmaire DC(36), Savatowky DJ(36), Vrillac MJ(36), Nakache MC(36), D’Hardemare
DV(36), Belamri ML(36), Mesnage DV(37), Bonnet DC(37), Correa Lino DJ Jr(37),
Decrocq DC(37), Boulin DA(37), Barre MI(37), Manouvrier MJ(37), Gardel DB(37),
Jarraya PB(37), Ziz MC(37), Prette ML(37), Douzane MH(37), Gay D(38), Bonicel
R(38), El Mountassir F(38), Fischer C(38), Mangin JF(38), Chupin M(38),
Cointepas Y(38), Accart B(39), Gelé P(39), Fievet F(39), Chabel M(39),
Derenaucourt V(39), Facon L(39), Njosse YT(39), Deplanque D(39), Duhamel A(40),
Djemmane L(40), Duflot F(40).
Author information:
(1)Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France.
Electronic address: .
(2)Psychiatry Department of the University Hospital of Toulouse, CHU Purpan,
Toulouse, France.
(3)Service de neurologie, Centre Hospitalier de Brive-la-Gaillarde, France;
Centre Expert Parkinson, CHU de Limoges, France.
(4)Service de neurologie C – Hôpital Neurologique – 59 boulevard Pinel 69003
Lyon – Hospices Civils de Lyon, France.
(5)Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie
et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La
Timone, NS-PARK/FCRIN Network, Marseille, France.
(6)Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France;
et Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and
CNRS UMR 7225, and Institut du Cerveau, F-75013, Paris, France.
(7)Department of Neurology, Hôpital Fondation Rothschild, Paris, France.
(8)Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France;
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center,
Clinical Investigation Center CIC1436, University Hospital of Toulouse,
NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse,
NS-PARK/FCRIN Network, France.
(9)Department of Clinical Pharmacology and Neurosciences, Parkinson Expert
Center, Clinical Investigation Center CIC1436, University Hospital of Toulouse,
NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse,
NS-PARK/FCRIN Network, France.
(10)Department of Medical Pharmacology, Neurology and Movement Disorders
Department, Referent Center of Parkinson’s disease, CHU of Lille, Univ. Lille
Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN
Network, France.
(11)Service de Neurologie, Unité des Mouvements Anormaux, Foch Hospital,
Suresnes, France; Université de Versailles Paris-Saclay, INSERM U992, CEA
Neurospin, Saclay, France.
(12)Department of Neurology, Rouen University Hospital and University of Rouen,
France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation
and Communication, Mont-Saint-Aignan, France.
(13)Service de neurologie, CHU Rennes, CIC INSERM, 1414, Rennes, France.
(14)Université Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal,
Clermont-Ferrand University Hospital, Neurology department, France.
(15)Institut des Maladies neurodégénératives, Pôle des neurosciences cliniques,
CHU Bordeaux, France; Service de neurophysiologie clinique de l’enfant et de
l’adulte, Pôle des neurosciences cliniques, CHU Bordeaux, France.
(16)Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg,
France; Institut de Génétique et de Biologie Moléculaire et Cellulaire,
INSERM-U964/CNRSUMR7104/Université de Strasbourg, Illkirch-Graffenstaden,
France; Fédération de Médecine Translationnelle de Strasbourg, Université de
Strasbourg, Strasbourg, France.
(17)Neurology Department of the University Hospital of Nancy, CHRU de Nancy,
Nancy, France.
(18)CHU Nice, Department of Psychiatry and Psychotherapy, Nice, France.
(19)Department of Neurology, Department of Neurosurgery, Expert Centre for
Parkinson’s disease, Amiens University Hospital, EA 4559 Laboratoire de
Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules
Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens,
France.
(20)Department of Neurology, Expert Centre for Parkinson’s Disease, University
Hospital of Nantes, Nantes, France.
(21)Lille University Hospital, France.
(22)AP-HP, Paris, France.
(23)Nantes University Hospital, France.
(24)Clermont-Ferrand University Hospital, France.
(25)AP-HM, Marseille, France.
(26)Poitiers University Hospital, France.
(27)Rennes University Hospital, France.
(28)Bordeaux University Hospital, France.
(29)Toulouse University Hospital, France.
(30)Rouen University Hospital, France.
(31)Strasbourg University Hospital, France.
(32)Nice University Hospital, France.
(33)Amiens University Hospital, France.
(34)Lyon University Hospital, France.
(35)Nancy University Hospital, France.
(36)Rotschild fondation of Paris, France.
(37)Foch Hospital of Paris-Saclay University, France.
(38)CATI, MRI acquisition Management, Preprocessing and data Management, France.
(39)CRB of Lille (Center of Biological Resources), France.
(40)Data Management of Lille, France.
INTRODUCTION: There is a growing interest in personality evaluation in
Parkinson’s disease (PD), following observations of specific temperaments in PD
patients. Therefore, our objective was to evaluate personality dimensions from
the Temperament and Character Inventory (TCI) in a cohort of fluctuating PD
patients considered for deep brain stimulation.
METHODS: Fluctuating PD patients from the PREDISTIM cohort were included.
Description of TCI dimensions and comparison with a French normative cohort were
performed. Pearson correlations between TCI dimensions and motor, behavioral and
cognitive variables were investigated. Structural and internal consistency
analysis of the TCI were further assessed.
RESULTS: The 570 PD patients presented significant higher scores in Harm
Avoidance, Reward Dependence, Persistence, Self-Directedness and Cooperativeness
and significant lower scores in Self-Transcendence compared to the French
normative cohort; only Novelty Seeking scores were not different. Harm Avoidance
and Self-directedness scores were correlated with PDQ-39 total, HAMD, HAMA
scores, and anxiolytic/antidepressant treatment. Novelty Seeking scores were
correlated with impulsivity. Pearson correlations between TCI dimensions,
principal component analysis of TCI sub-dimensions and Cronbach’s alpha
coefficients showed adequate psychometric proprieties.
CONCLUSION: The TCI seems to be an adequate tool to evaluate personality
dimensions in PD with good structural and internal consistencies. These
fluctuating PD patients also have specific personality dimensions compared to
normative French population. Moreover, Harm Avoidance and Self-Directedness
scores are associated with anxio-depressive state or quality of life and, and
Novelty Seeking scores with impulsivity.
Copyright © 2022 Elsevier Ltd. All rights reserved.